期刊文献+

^(18)F-FDG PET/CT对治疗前淋巴瘤分期的临床价值 被引量:4

THE CLINICAL VALUE OF ^(18) F-FDG PET/CT FOR PRE-TREATMENT STAGING OF LYMPHOMA
下载PDF
导出
摘要 目的探讨18F-FDG PET/CT显像对治疗前淋巴瘤临床分期的价值。方法回顾性分析63例初次诊断为淋巴瘤病人的PET/CT及常规影像学检查结果。结果 PET/CT与常规影像学检查对63例淋巴瘤病人分期的一致率为30.2%(19/63)。与常规影像学检查结果相比,18F-FDG PET/CT显像使69.8%(44/63)的淋巴瘤病人临床分期发生改变。其中17.4%(11/63)的病例在PET/CT检查中发现有多区域淋巴结及多个结外器官受累,肝或骨髓受累,淋巴瘤的临床分期从Ⅰ期上调至Ⅳ期;有25.4%(16/63)的病例在PET/CT检查中发现多区域淋巴结累及,分期上调一期;其余27.0%(17/63)的病例在PET/CT检查中发现多区域淋巴结或多个结外器官受累,临床分期上调两期。结论 18F-FDG PET/CT显像对治疗前淋巴瘤临床分期的价值优于常规影像学检查,有利于制定合理有效的治疗方案。 Objective To evaluate the value of is F-FDG PET/CT imaging in pretherapy clinical staging of lymphoma. Methods A retrospective review was done in 63 patients with lymphoma diagnosed at first visit, their PET/CT and routine imaging results were analyzed. Results The concordance rate of 18FFDG PET/CT with routine imaging examination was 30.2% (19/63) in staging of 63 patients with lymphoma. Compared with routine imaging examination, 69.8% (44/63) of the patients with image of 18F-FDG PET/CT showed changes of clinical stage. Of whom, 17.4% (11/63) on PET/CT showed multi-regional lymphnode or organs-liver or bone marrow-were involved, the stage of the lymphoma was raised from stage 1 to stage 4, and 25.4% of the patients were found to have multi-regional lymphnodes involved, the stage was up-regulated one phase; and 27.0% of patients with the grade to be raised by two stages because of lymphnode involvement in multiple regions and organs outside the lymphnodes. Conclusion 18F-FDG PET/CT is superior to routine imaging examination in pretherapy clinical staging of lympho- ma, which is helpful in making a reasonable and effective therapeutic schedule.
出处 《齐鲁医学杂志》 2014年第6期513-515,共3页 Medical Journal of Qilu
关键词 淋巴瘤 体层摄影术 发射型计算机 氟脱氧葡萄糖F18 lymphoma tomography, emission-computed fluorodeoxyglucose F18
  • 相关文献

参考文献9

  • 1CERCI J J, TRINDADE E, BUCCHERI V, et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions[J]. Ciin Lymphoma Myeloma Leuk, 2011,11(4) :314-320.
  • 2ILICA A T, KOCACELEBI K, SAVAS R, et al. Imaging of extranodal lymphoma with PET/CT[J]. Clin Nucl Med, 2011,36(10) ; e127-e138.
  • 3PAES F M, KALKANIS D G, SIDERAS P A, et al. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease[J]. Radiographies, 2010,30(1) ~ 269-291.
  • 4CROCCHIOLO R, FALLANCA F, GIOVACCHINI G, et al. Role of 18 FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin' s lymphoma[J]. Ann Hematol, 2009,88(12) :1229-1236.
  • 5BABA S, ABE K, ISODA T, et al. Impact of FDG-PET/CT in the management of lymphoma[J]. Ann Nucl Med, 2011,25 (10) :701-716.
  • 6HUTCHINGS M, BARRINGTON S F. PET/CT for therapy response assessment in lymphoma[J]. J Nucl Med, 2009,50 (Suppl 1) :21S-30S.
  • 7周莉莉,王椿,赵晋华,颜式可,高彦荣,蔡琦,姜杰玲,万理萍,杨隽,卫菊,赵旻,白海涛.^18氟-氟代脱氧葡萄糖-正电子发射计算机断层显像在淋巴瘤分期和疗效评价中的作用[J].中华血液学杂志,2009,30(4):233-236. 被引量:9
  • 8FUEGER B J, YEOM K, CZERNIN J, et al. Comparison of CT, PET, and PET/CT for staging of patients with indolent non Hodgkin~s lymphoma[J]. Mol Imaging Biol, 2009, 11 (4) :269 -274.
  • 9WEILER-SAGIE M, BUSHELEV O, EPELBAUM R, et aI. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients[J]. J Nucl Med, 2010,51(1):25-30.

二级参考文献17

  • 1Buchmann I, Guhlmann CA, Eisner K, et al. F-18-FDG PET for primary diagnosis differential diagnosis of pIeural processes. Nuklearmedizin, 1999, 38:319-322.
  • 2Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer, 1998, 83: 918-924.
  • 3Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer, 1998, 82:1160-1166.
  • 4Buehmann I, Rdnhardt M, Elsner K, et al. 2-( fluorine-18 ) fluoro- 2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bieenter trial. Cancer,2001,91:889-899.
  • 5Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2001.
  • 6Tatsumi M, Kitayama H, Sugahara H, et al. Whole-body hybrid PET with ^18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med, 2001, 42:601-608.
  • 7Dorfman RE, Alpern MB, Gross BH, et al. Upper abdominal lymph nodes : criteria for normal size determined with CT. Radialogy, 1991,180:319-322.
  • 8Cheson BD, Homing SJ, Coiffier B, et al. Report of an intemational workshop to standardize response criteria for non-Hodgkin' s tymphomas. NCI Sponsored International Working Group. J Clin Oncol, 1999,17 : 1244.
  • 9Cheson BD, Pfistner B, Juweid ME ,et al. Revised response criteria for malignant lymphoma. J Clin Oncol,2007, 25:579-586.
  • 10Freudenberg LS, Antoch G, Schutt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging, 2004, 31:325-329.

共引文献8

同被引文献49

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部